, Tracking Stock Market Picks
Enter Symbol:
Sarepta Therapeutics Inc (SRPT) [hlAlert]

Neutral SRPT

Sarepta Therapeutics Inc (SRPT) rated Neutral by Piper Jaffray

Posted on: Friday,  Jan 15, 2016  12:25 PM ET by Piper Jaffray

Piper Jaffray rated Neutral Sarepta Therapeutics Inc (NASDAQ: SRPT) on 01/15/2016. Previously Piper Jaffray rated Underweight Sarepta Therapeutics Inc (NASDAQ: SRPT) on
11/12/2013., when the stock price was $15.45. Since then, Sarepta Therapeutics Inc has gained 33.79% as of 12/23/2013's recent price of $20.67.
If you would have followed the previous Piper Jaffray's recommendation on SRPT, you would have lost 25.25% of your investment in 41 days.

AVI BioPharma develops therapeutic products for the treatment of life-threatening diseases using third-generation NEUGENE antisense drugs and ESPRIT exon skipping technology. AVI's lead NEUGENE antisense compound is designed to target cell proliferation disorders, including cardiovascular restenosis. In addition to targeting specific genes in the body, AVI's antiviral program uses NEUGENE antisense compounds to combat disease by targeting single-stranded RNA viruses, including West Nile virus, hepatitis C virus, dengue virus, Ebola virus and influenza A virus. AVI's NEUGENE-based ESPRIT technology will initially be applied to potential treatments for Duchenne muscular dystrophy.

At Piper Jaffray, we understand there’s no substitute for relevant and timely research. That's why we provide: * fundamental and technical research * value-added investment ideas * market analysis With the information our research team provides, you’ll make better and more informed decisions for your portfolio.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
1/18/2016 8:25 AM Hold
as of 10/17/2014
1 Week   
1 Month   
3 Months   
1 YTD   
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
1/15/2016 12:25 PM Hold
12/23/2013 8:25 AM Hold
11/12/2013 8:25 AM Sell
7/24/2013 9:25 AM Hold

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy